# The Third Xiangya Hospital of Central South University: Phase 1 study in Healthy Participants (66 participants)

**Score:** 30/100

| Field | Value |
|---|---|
| Sponsor | The Third Xiangya Hospital of Central South University |
| Sponsor type | Academic and hospital |
| Study | Safety, Tolerability, and Pharmacokinetics of DM1001 Transdermal Patch in Healthy Chinese Participants |
| NCT ID | NCT07844954 |
| Phase | Phase 1 |
| Status | not yet recruiting |
| Conditions | Healthy Participants |
| Intervention types | drug |
| Target enrollment | 66 |
| Posted | 2026-09-28 |
| Planned start | 2026-09-30 |
| Event | Newly registered study |
| Event date | 2026-09-28 |

## Why this score
- Not yet recruiting: vendors still being chosen.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07844954). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.